RESUMO
Ligneous conjunctivitis is a rare form of chronic and recurrent bilateral conjunctivitis, in which thick membranes develop on the tarsal conjunctiva and on other mucosae. We report the case of a 55-year old female patient with bilateral ligneous conjunctivitis who was successfully treated with 50% heterologous serum. There was no recurrence or side effects after one-year follow-up. We suggest the use of 50% heterologous serum should be further studied to better determine its efficacy as a treatment option for ligneous conjunctivitis.
Assuntos
Plasminogênio/deficiência , Soro , Conjuntivite/patologia , Feminino , Humanos , Pessoa de Meia-Idade , Plasminogênio/uso terapêutico , Dermatopatias Genéticas/patologia , Resultado do TratamentoRESUMO
ABSTRACT Ligneous conjunctivitis is a rare form of chronic and recurrent bilateral conjunctivitis, in which thick membranes develop on the tarsal conjunctiva and on other mucosae. We report the case of a 55-year old female patient with bilateral ligneous conjunctivitis who was successfully treated with 50% heterologous serum. There was no recurrence or side effects after one-year follow-up. We suggest the use of 50% heterologous serum should be further studied to better determine its efficacy as a treatment option for ligneous conjunctivitis.
RESUMO A conjuntivite lenhosa é uma forma rara de conjuntivite bilateral crônica e recorrente, na qual há formação de membranas espessas na conjuntiva tarsal e em outras mucosas. Relatamos o caso de uma paciente de 55 anos com conjuntivite lenhosa bilateral, que obteve sucesso no tratamento com soro heterólogo em concentração de 50%. Não houve recorrência após um ano de seguimento e nem efeitos colaterais ao tratamento. Dessa forma, o uso de soro heterólogo a 50% poderia ser mais estudado para melhor avaliação de sua eficácia como opção de tratamento para a conjuntivite lenhosa.
Assuntos
Humanos , Feminino , Plasminogênio/deficiência , Soro , Plasminogênio/uso terapêutico , Dermatopatias Genéticas/patologia , Resultado do Tratamento , Conjuntivite/patologia , Pessoa de Meia-IdadeRESUMO
The study of the National Institute of Neurological Disorders and Stroke (NINDS) proved that the use of the recombinant tissue plasminogen activator (rtPA) within the first 3 hours since the beginning of the symptomatology of the acute ischemis stroke (AIS) is as well safe as effective...These preliminary data reported in our study show that a strict protocol of thrombolysis IV with rtPA in AIS is feasible to be carried on with good results in a high complexity Center.
Assuntos
Humanos , Idoso , Ataque Isquêmico Transitório/patologia , Ataque Isquêmico Transitório/terapia , Testes de Coagulação Sanguínea , Bombas de Infusão , Plasminogênio/administração & dosagem , Plasminogênio/uso terapêutico , Terapia Trombolítica , Tomografia Computadorizada por Raios X , Contagem de PlaquetasRESUMO
Recent studies have shown the possibility to treat cancer with drugs that affect the formation of new blood vessels instead of attacking directly the malignant cell. This relatively new field in the area of oncology on angiogenesis inhibition has expanded the therapeutic option for malignant diseases. We will discuss several antiangiogenesis drugs in clinical development and their mechanism of action. Some of these drugs include: angiostatin, metalloproteinase inhibitors, thalidomide, tamoxifen, interferons and others. The use of antiangiogenic agents, both in combination with other treatment modalities in the acute setting as well as long-term maintenance or prevention of cancer, is at present one of the better promises in the war against cancer.
Assuntos
Inibidores da Angiogênese/uso terapêutico , Neoplasias/irrigação sanguínea , Neovascularização Patológica/tratamento farmacológico , Angiostatinas , Ensaios Clínicos como Assunto , Colágeno/uso terapêutico , Endostatinas , Humanos , Fragmentos de Peptídeos/uso terapêutico , Plasminogênio/uso terapêuticoRESUMO
Recent studies have shown the possibility to treat cancer with drugs that affect the formation of new blood vessels instead of attacking directly the malignant cell. This relatively new field in the area of oncology on angiogenesis inhibition has expanded the therapeutic option for malignant diseases. We will discuss several antiangiogenesis drugs in clinical development and their mechanism of action. Some of these drugs include: angiostatin, metalloproteinase inhibitors, thalidomide, tamoxifen, interferons and others. The use of antiangiogenic agents, both in combination with other treatment modalities in the acute setting as well as long-term maintenance or prevention of cancer, is at present one of the better promises in the war against cancer.
Assuntos
Humanos , Inibidores da Angiogênese/uso terapêutico , Neoplasias/irrigação sanguínea , Neovascularização Patológica/tratamento farmacológico , Ensaios Clínicos como Assunto , Colágeno/uso terapêutico , Fragmentos de Peptídeos/uso terapêutico , Plasminogênio/uso terapêuticoRESUMO
PURPOSE: To relate our experience with thrombolytic therapy in 8 patients with cardiac metal prosthesis complicated with thrombosis. METHODS: Eight patients with clinical and echocardiographic diagnosis of cardiac valvar prosthesis thrombosis were treated. RESULTS: The treatment efficacy was evaluated by clinical and echocardiographic improvement. The authors recognized improvement in all 8 patients. One case of hemorrhage was observed (coxo-femoral articulation). Late death were observed twice: 24 months after, sudden death and 30 months later by hemorrhagic stroke. CONCLUSION: The results indicated that thrombolytic therapy is best way to treat patients with cardiac valve thrombosis, instead of surgical treatment.
Assuntos
Trombose Coronária/tratamento farmacológico , Próteses Valvulares Cardíacas/efeitos adversos , Plasminogênio/uso terapêutico , Estreptoquinase/uso terapêutico , Terapia Trombolítica , Adulto , Trombose Coronária/etiologia , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
PURPOSE--To relate our experience with thrombolytic therapy in 8 patients with cardiac metal prosthesis complicated with thrombosis. METHODS--Eight patients with clinical and echocardiographic diagnosis of cardiac valvar prosthesis thrombosis were treated. RESULTS--The treatment efficacy was evaluated by clinical and echocardiographic improvement. The authors recognized improvement in all 8 patients. One case of hemorrhage was observed (coxo-femoral articulation). Late death were observed twice: 24 months after, sudden death and 30 months later by hemorrhagic stroke. CONCLUSION--The results indicated that thrombolytic therapy is best way to treat patients with cardiac valve thrombosis, instead of surgical treatment
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Estreptoquinase/uso terapêutico , Próteses Valvulares Cardíacas/efeitos adversos , Plasminogênio/uso terapêutico , Terapia Trombolítica , Trombose Coronária/tratamento farmacológico , Seguimentos , Trombose Coronária/etiologiaAssuntos
Fibrinolíticos/uso terapêutico , Infarto do Miocárdio/tratamento farmacológico , Fibrinolíticos/farmacologia , Humanos , Plasminogênio/farmacologia , Plasminogênio/uso terapêutico , Ativador de Plasminogênio Tecidual/farmacologia , Ativador de Plasminogênio Tecidual/uso terapêutico , alfa 2-Antiplasmina/farmacologia , alfa 2-Antiplasmina/uso terapêuticoRESUMO
Thirteen patients with less than 5 hours of the onset of symptoms of acute myocardial infarction underwent selective coronary angiography. Ten of them had angiographic signs of coronary thrombosis. In these ten patients 15 mgs of an acylated streptokinase-plasminogen complex (BRL 26921 Beecham Farmaceuticals) were administered intravenously. Total angiographic recanalization was observed in 7 patients. The coronary arteries involved were the left anterior descending in 4 cases and the right coronary artery in 3. In 8 out of the 10 patients significant diminution of injury pattern in EKG was registered, however in all of them the necrosis pattern supervened. Prolongation of the thrombin and thromboplastin times, as well as an important fibrinogen disminution were documented in all instances. There were not complications related to the administration of the drug. An increase of muscle enzimes was documented in all cases. The follow-up was uneventfull with excellent results in all the patients. This study proves that with IV trombolitic therapy coronary recanalization can be achieved in the mayority of the patients; however there is no question that myocardial infarction finally ocurred. We speculate about the possibility of avoiding infarction by the administration of the drug within the first hour after the onset of the symptoms.